 Lisa Brents
Concepts (165)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naphthalenes | 9 | 2015 | 127 | 1.850 |
Why?
| | Indoles | 10 | 2015 | 291 | 1.750 |
Why?
| | Receptor, Cannabinoid, CB1 | 9 | 2015 | 126 | 1.470 |
Why?
| | Personality Disorders | 2 | 2018 | 22 | 1.250 |
Why?
| | Cannabinoids | 3 | 2013 | 102 | 0.950 |
Why?
| | Behavioral Research | 1 | 2021 | 8 | 0.840 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 2021 | 15 | 0.830 |
Why?
| | Morphine | 1 | 2021 | 101 | 0.790 |
Why?
| | Narcotics | 1 | 2021 | 111 | 0.780 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2018 | 20 | 0.690 |
Why?
| | Personality | 1 | 2018 | 32 | 0.690 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2019 | 177 | 0.670 |
Why?
| | Buprenorphine | 1 | 2019 | 120 | 0.650 |
Why?
| | Fetus | 1 | 2019 | 229 | 0.650 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 210 | 0.620 |
Why?
| | Endocannabinoids | 1 | 2016 | 27 | 0.600 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 259 | 0.580 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 333 | 0.550 |
Why?
| | Receptors, Cannabinoid | 2 | 2012 | 19 | 0.550 |
Why?
| | Stress, Psychological | 1 | 2015 | 286 | 0.460 |
Why?
| | Child Abuse | 1 | 2015 | 173 | 0.450 |
Why?
| | Hemiterpenes | 1 | 2011 | 10 | 0.440 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.430 |
Why?
| | Stilbenes | 1 | 2011 | 61 | 0.420 |
Why?
| | Plant Extracts | 1 | 2013 | 205 | 0.410 |
Why?
| | Glucuronosyltransferase | 2 | 2012 | 156 | 0.410 |
Why?
| | Behavior, Animal | 1 | 2012 | 227 | 0.390 |
Why?
| | Animals | 15 | 2021 | 14801 | 0.390 |
Why?
| | Pain | 1 | 2013 | 389 | 0.390 |
Why?
| | Body Temperature | 4 | 2015 | 85 | 0.370 |
Why?
| | Binding, Competitive | 4 | 2013 | 134 | 0.370 |
Why?
| | Animals, Newborn | 2 | 2021 | 402 | 0.350 |
Why?
| | Substance-Related Disorders | 1 | 2013 | 624 | 0.320 |
Why?
| | Rats | 3 | 2021 | 3599 | 0.300 |
Why?
| | Hydroxylation | 4 | 2012 | 61 | 0.280 |
Why?
| | Hypothermia | 2 | 2015 | 41 | 0.260 |
Why?
| | Receptor, Cannabinoid, CB2 | 3 | 2013 | 60 | 0.260 |
Why?
| | Mice | 9 | 2015 | 6389 | 0.240 |
Why?
| | Pregnancy | 2 | 2021 | 2432 | 0.230 |
Why?
| | Female | 7 | 2021 | 28888 | 0.230 |
Why?
| | Motor Activity | 2 | 2015 | 269 | 0.220 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 25 | 0.210 |
Why?
| | Automation | 1 | 2021 | 23 | 0.210 |
Why?
| | Video Recording | 1 | 2021 | 94 | 0.200 |
Why?
| | ROC Curve | 1 | 2021 | 256 | 0.200 |
Why?
| | Movement | 1 | 2021 | 109 | 0.190 |
Why?
| | Cricetinae | 4 | 2013 | 211 | 0.190 |
Why?
| | Molecular Structure | 4 | 2013 | 334 | 0.190 |
Why?
| | Software | 1 | 2021 | 281 | 0.170 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 970 | 0.170 |
Why?
| | Risk | 1 | 2019 | 361 | 0.170 |
Why?
| | CHO Cells | 3 | 2013 | 130 | 0.170 |
Why?
| | Ligands | 3 | 2013 | 254 | 0.160 |
Why?
| | Humans | 14 | 2018 | 52865 | 0.150 |
Why?
| | Menstrual Cycle | 1 | 2016 | 10 | 0.150 |
Why?
| | Young Adult | 2 | 2018 | 4295 | 0.150 |
Why?
| | Fertility | 1 | 2016 | 37 | 0.150 |
Why?
| | Progesterone | 1 | 2016 | 81 | 0.150 |
Why?
| | Pentacyclic Triterpenes | 2 | 2012 | 7 | 0.150 |
Why?
| | Brain | 3 | 2015 | 1458 | 0.150 |
Why?
| | Kinetics | 3 | 2012 | 740 | 0.140 |
Why?
| | Receptors, Opioid, mu | 2 | 2013 | 44 | 0.140 |
Why?
| | Protein Binding | 3 | 2013 | 784 | 0.140 |
Why?
| | Male | 6 | 2018 | 28240 | 0.140 |
Why?
| | Drug Tolerance | 1 | 2015 | 63 | 0.140 |
Why?
| | Personality Assessment | 1 | 2015 | 20 | 0.140 |
Why?
| | Mice, Inbred Strains | 2 | 2012 | 211 | 0.140 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2012 | 197 | 0.130 |
Why?
| | Cannabis | 1 | 2016 | 117 | 0.130 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 332 | 0.130 |
Why?
| | Cyclohexanols | 1 | 2013 | 22 | 0.130 |
Why?
| | Membranes | 1 | 2013 | 17 | 0.130 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2015 | 358 | 0.120 |
Why?
| | Mass Spectrometry | 2 | 2012 | 324 | 0.120 |
Why?
| | Analysis of Variance | 1 | 2015 | 674 | 0.120 |
Why?
| | Recombinant Proteins | 2 | 2012 | 594 | 0.120 |
Why?
| | Drug Synergism | 1 | 2013 | 173 | 0.120 |
Why?
| | Drug Interactions | 1 | 2013 | 220 | 0.120 |
Why?
| | Anticarcinogenic Agents | 1 | 2012 | 47 | 0.120 |
Why?
| | Conditioning, Operant | 1 | 2013 | 109 | 0.120 |
Why?
| | Quinuclidines | 1 | 2013 | 43 | 0.120 |
Why?
| | YY1 Transcription Factor | 1 | 2012 | 8 | 0.120 |
Why?
| | Triterpenes | 1 | 2012 | 14 | 0.110 |
Why?
| | Psychomotor Performance | 1 | 2013 | 170 | 0.110 |
Why?
| | Drug Partial Agonism | 1 | 2012 | 7 | 0.110 |
Why?
| | Drug Antagonism | 1 | 2012 | 9 | 0.110 |
Why?
| | Pain Measurement | 1 | 2013 | 262 | 0.110 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2012 | 43 | 0.110 |
Why?
| | Prenylation | 1 | 2011 | 3 | 0.110 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 24 | 0.110 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2011 | 12 | 0.110 |
Why?
| | Isoproterenol | 1 | 2012 | 65 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 1 | 2012 | 51 | 0.110 |
Why?
| | Receptor, erbB-2 | 1 | 2012 | 84 | 0.110 |
Why?
| | Piperidines | 1 | 2012 | 102 | 0.110 |
Why?
| | GTP-Binding Proteins | 1 | 2012 | 95 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1067 | 0.110 |
Why?
| | Narcotic Antagonists | 1 | 2012 | 123 | 0.110 |
Why?
| | Pyrazoles | 1 | 2012 | 118 | 0.110 |
Why?
| | Biological Availability | 1 | 2011 | 141 | 0.110 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2012 | 90 | 0.110 |
Why?
| | Protein Transport | 1 | 2012 | 205 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 208 | 0.100 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2012 | 149 | 0.100 |
Why?
| | Middle Aged | 2 | 2018 | 13614 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2012 | 171 | 0.100 |
Why?
| | Cell Membrane | 1 | 2012 | 283 | 0.100 |
Why?
| | Adult | 2 | 2018 | 14316 | 0.100 |
Why?
| | Plaque, Amyloid | 1 | 2010 | 18 | 0.100 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2010 | 17 | 0.100 |
Why?
| | Down-Regulation | 1 | 2012 | 402 | 0.100 |
Why?
| | Extracellular Space | 1 | 2010 | 48 | 0.100 |
Why?
| | Lectins, C-Type | 1 | 2010 | 34 | 0.100 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2010 | 32 | 0.100 |
Why?
| | Models, Molecular | 1 | 2011 | 430 | 0.100 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 442 | 0.100 |
Why?
| | Risk Factors | 1 | 2018 | 3984 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1571 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2013 | 1842 | 0.090 |
Why?
| | Protein Processing, Post-Translational | 1 | 2010 | 185 | 0.090 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 217 | 0.080 |
Why?
| | MicroRNAs | 1 | 2012 | 366 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 1810 | 0.080 |
Why?
| | Adolescent | 1 | 2015 | 6866 | 0.060 |
Why?
| | Neoplasms | 1 | 2012 | 1258 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2012 | 1272 | 0.060 |
Why?
| | Injections, Intraperitoneal | 1 | 2014 | 67 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2014 | 120 | 0.030 |
Why?
| | Stereoisomerism | 1 | 2013 | 135 | 0.030 |
Why?
| | Psychotropic Drugs | 1 | 2013 | 81 | 0.030 |
Why?
| | Drug Inverse Agonism | 1 | 2012 | 18 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2012 | 7 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A2 | 1 | 2012 | 47 | 0.030 |
Why?
| | Pyrans | 1 | 2012 | 27 | 0.030 |
Why?
| | Cricetulus | 1 | 2012 | 102 | 0.030 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 5 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 79 | 0.030 |
Why?
| | Morpholines | 1 | 2012 | 68 | 0.030 |
Why?
| | Glucuronides | 1 | 2012 | 61 | 0.030 |
Why?
| | Cyclic AMP | 1 | 2012 | 117 | 0.030 |
Why?
| | Mice, Nude | 1 | 2012 | 278 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2012 | 138 | 0.030 |
Why?
| | rab GTP-Binding Proteins | 1 | 2012 | 44 | 0.030 |
Why?
| | Microsomes, Liver | 1 | 2012 | 214 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2012 | 248 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 395 | 0.030 |
Why?
| | Brevican | 1 | 2010 | 8 | 0.020 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 15 | 0.020 |
Why?
| | Culture Media | 1 | 2010 | 105 | 0.020 |
Why?
| | Brain Chemistry | 1 | 2010 | 84 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 275 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 721 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 712 | 0.020 |
Why?
| | Neurons | 1 | 2012 | 485 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 725 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 1503 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 1124 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 896 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 1147 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2012 | 451 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1140 | 0.020 |
Why?
| | Cell Line | 1 | 2010 | 1226 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2010 | 328 | 0.020 |
Why?
| | Liver | 1 | 2012 | 1266 | 0.020 |
Why?
| | Apoptosis | 1 | 2012 | 1357 | 0.020 |
Why?
|
|
Brents's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|